Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunotherapeutics for head and neck squamous cell carcinoma stem cells.

Literature DB >> 31996933

Immunotherapeutics for head and neck squamous cell carcinoma stem cells.

X Qian^1,2,3,4, F Leonard⁵, Y Wenhao⁴, H Sudhoff⁶, T K Hoffmann⁷, S Ferrone⁸, A M Kaufmann⁹, A E Albers¹⁰.

Abstract

Cancer stem cell (CSC)-related therapy resistance has become a new obstacle to the successful application of cancer treatment and head and neck squamous cell carcinoma (HNSCC) is no exception to this finding. Head and neck squamous cell carcinoma is highly immune-suppressive, and recently the immune suppression and invasion of HNSCC-CSCs have been characterized. These characteristics have received research and clinical attention because they would enable the stratification of patients into specific cancer subtypes and, consequently, the establishment of new therapeutic approaches with improved efficacy. This review discusses the feasibility of CSC-targeted strategies and their incorporation with nanotechnology to improve the efficacy of cancer immunotherapy.

Entities: Chemical

Keywords: Cancer nanomedicine; Cancer stem cell; Cancer vaccine; Immunotherapy; Nanotechnology

Mesh：

Year: 2020 PMID： 31996933 DOI： 10.1007/s00106-020-00819-y

Source DB: PubMed Journal: HNO ISSN： 0017-6192 Impact factor: 1.330

57 in total

1. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.

Authors: Andreas Albers; Koji Abe; Jennifer Hunt; Jun Wang; Andres Lopez-Albaitero; Carsten Schaefer; William Gooding; Theresa L Whiteside; Soldano Ferrone; Albert DeLeo; Robert L Ferris
Journal: Cancer Res Date: 2005-12-01 Impact factor: 12.701

2. Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting.

Authors: Yangyang Hu; Lin Lu; Yang Xia; Xin Chen; Alfred E Chang; Robert E Hollingsworth; Elaine Hurt; John Owen; Jeffrey S Moyer; Mark E P Prince; Fu Dai; Yangyi Bao; Yi Wang; Joel Whitfield; Jian-Chuan Xia; Shiang Huang; Max S Wicha; Qiao Li
Journal: Cancer Res Date: 2016-06-20 Impact factor: 12.701

Review 3. The molecular landscape of head and neck cancer.

Authors: C René Leemans; Peter J F Snijders; Ruud H Brakenhoff
Journal: Nat Rev Cancer Date: 2018-03-02 Impact factor: 60.716

4. Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors: Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal: Clin Cancer Res Date: 2014-02-28 Impact factor: 12.531

5. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.

Authors: Serena Pellegatta; Pietro Luigi Poliani; Daniela Corno; Francesca Menghi; Francesco Ghielmetti; Blanca Suarez-Merino; Valentina Caldera; Sara Nava; Maria Ravanini; Fabio Facchetti; Maria Grazia Bruzzone; Gaetano Finocchiaro
Journal: Cancer Res Date: 2006-11-01 Impact factor: 12.701

6. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.

Authors: Andrés López-Albaitero; Jayakar V Nayak; Takeshi Ogino; Avinash Machandia; William Gooding; Albert B DeLeo; Soldano Ferrone; Robert L Ferris
Journal: J Immunol Date: 2006-03-15 Impact factor: 5.422

7. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors: Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245

Immunotherapeutics for head and neck squamous cell carcinoma stem cells.

1. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.

2. Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting.

Review 3. The molecular landscape of head and neck cancer.

4. Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

5. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.

6. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.

7. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Review 8. The role of cancer stem cells in the modulation of anti-tumor immune responses.

9. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles.

Review 10. Improving cancer immunotherapy through nanotechnology.

Review 1. Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck.

Review 2. Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care.